SCD is only one blood disorder that can benefit from Aruvant’s modified fetal hemoglobin–based gene therapy. The company is already working on applying ARU-1801 to the treatment of β-thalassemia.

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Neurocrine (NBIX – Research Report), with a ...

inherited RBC disorders, or as a response to drugs or other toxins Howell-Jolly Bodies Nuclear remnants seen in RBCs after Wright's staining Seen in types of anemia, asplenia/hyposplenia ...

RBC analyst Brian Abrahams in a note said the ... uncertainties" about the drug’s future in the rare metabolic disorder, where no approved treatments exist. Abrahams said the FDA may require ...